The outcomes of primary membranous nephropathy treated with cyclophosphamide are superior to calcineurin inhibitors in patients with renal vascular lesions: A multi-center retrospective cohort study
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Cyclophosphamide (CTX) therapy significantly improves renal survival in primary membranous nephropathy (PMN) patients with vascular lesions compared to calcineurin inhibitors (CNIs). This finding offers a clearer treatment path for this patient group.
Area Of Science
- Nephrology
- Immunosuppressive therapy
- Renal pathology
Background
- Primary membranous nephropathy (PMN) is a leading cause of nephrotic syndrome in adults.
- The optimal immunosuppressive strategy for PMN patients with renal vascular lesions remains unclear.
- Comparing cyclophosphamide (CTX) and calcineurin inhibitors (CNIs) is crucial for improving patient outcomes.
Purpose Of The Study
- To compare the efficacy of CTX-based therapy versus CNI-based therapy in patients with PMN and renal vascular lesions.
- To evaluate the impact of these treatments on renal survival and other key clinical outcomes.
- To identify specific patient subgroups that may benefit more from one therapy over the other.
Main Methods
- A retrospective study involving 761 patients with PMN from three Chinese centers (2003-2018).
- Propensity-score matching (PSM) was employed to minimize bias between CTX and CNI treatment groups.
- Primary endpoints included a 50% decline in eGFR, end-stage renal disease, or all-cause mortality; pathological vascular lesions were assessed via immunohistochemistry.
Main Results
- After PSM, no significant difference in proteinuria remission rates was observed between the CTX and CNI groups (p=0.10).
- CTX-based therapy demonstrated significantly better renal survival (median 156 months vs. 108 months; HR=0.31; p=0.001) compared to CNI-based therapy.
- Subgroup analyses revealed CTX superiority in patients with hyalinosis damage, arteriosclerosis, or hypertension (p<0.002 for all).
Conclusions
- CTX-based therapy offers a significant survival advantage for PMN patients with vascular lesions compared to CNIs.
- The findings suggest CTX as a preferred treatment option for specific PMN patient subgroups with vascular pathology.
- Further research may elucidate the mechanisms behind CTX's superior renal protection in these patients.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...